When will the patents on TENOFOVIR ALAFENAMIDE expire, and when will TENOFOVIR ALAFENAMIDE go generic?

Sponsor	Phase
Phichit Provincial Public Health Office, Ministry of Public Health, Thailand (Host institution)	PHASE4
Liver Foundation Thailand	PHASE4
Johns Hopkins University	PHASE1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	TENOFOVIR ALAFENAMIDE	tenofovir alafenamide fumarate	TABLET;ORAL	214226-001	Mar 30, 2023	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Apotex	TENOFOVIR ALAFENAMIDE FUMARATE	tenofovir alafenamide fumarate	TABLET;ORAL	213867-001	Mar 21, 2024		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 21, 2026

Tenofovir alafenamide (TAF) has become one of Gilead Sciences’ most valuable antiretroviral and antiviral platforms. Its commercial value comes primarily from combination HIV products, led by Biktarvy, with additional revenue from Descovy, Genvoya, Odefsey, Symtuza, and Vemlidy for chronic hepatitis B. TAF-containing products generated approximately $18 billion to $20 billion in annual revenue in 2023-2024, depending on product and reporting classification.

Biktarvy is the principal growth driver. Vemlidy provides a durable HBV revenue stream, while Descovy retains strategic value through HIV treatment and pre-exposure prophylaxis. The principal medium-term threat is generic erosion of individual products and older TAF combinations, although Gilead’s later-expiring formulation, combination, and method-of-use patents may delay broad substitution.

What is tenofovir alafenamide and why is it commercially important?

Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor prodrug of tenofovir. It delivers the active metabolite more efficiently into lymphoid and hepatic cells than tenofovir disoproxil fumarate (TDF), allowing lower dosing and generally lower circulating tenofovir exposure.

The commercial advantages over TDF include:

Lower systemic tenofovir concentrations.
Improved renal and bone safety profile in many patients.
Compatibility with single-tablet HIV regimens.
Use in both HIV and chronic hepatitis B.
A platform role in multiple fixed-dose combinations.

TAF is not marketed as a major standalone product. Its value is captured through branded combination products and Vemlidy.

Which products contain tenofovir alafenamide?

Product	TAF role	Active ingredients or therapeutic use	FDA approval
Genvoya	HIV treatment	Elvitegravir, cobicistat, emtricitabine, TAF	2015
Vemlidy	HBV treatment	TAF	2016
Descovy	HIV treatment and PrEP	Emtricitabine, TAF	2016; PrEP approval in 2019
Odefsey	HIV treatment	Emtricitabine, rilpivirine, TAF	2016
Biktarvy	HIV treatment	Bictegravir, emtricitabine, TAF	2018
Symtuza	HIV treatment	Darunavir, cobicistat, emtricitabine, TAF	2018

The products are approved for different populations and treatment settings. Descovy is approved for HIV PrEP in adults and adolescents at risk of sexually acquired HIV, but it is not indicated for individuals at risk from receptive vaginal sex under the original FDA label. Vemlidy is approved for chronic HBV in adults and certain pediatric patients with compensated liver disease. FDA labels define the approved populations and limitations. (U.S. Food and Drug Administration [FDA], 2015, 2016a, 2016b, 2018a, 2018b, 2019)

How large is the tenofovir alafenamide market?

The TAF market is concentrated in Gilead’s HIV and HBV portfolios. Biktarvy has expanded rapidly and now accounts for more than half of the identifiable TAF-containing product revenue.

TAF-containing product revenue trajectory

Product revenue, $ millions	2022	2023	2024
Biktarvy	10,393	11,847	approximately 13,400
Descovy	2,212	2,329	approximately 2,550
Genvoya	1,222	1,517	approximately 1,400
Odefsey	694	777	approximately 775
Symtuza	545	668	approximately 755
Vemlidy	1,027	1,043	approximately 1,100
Total identifiable TAF products	16,093	18,181	approximately 19,980

Source: Gilead Sciences annual reports and product revenue disclosures. Values for 2024 are rounded to reflect company reporting and product-level presentation. (Gilead Sciences, 2023, 2024, 2025)

Biktarvy revenue increased by roughly 14% in 2023 and by approximately 13% in 2024. Growth has come from patient additions, switching from older regimens, strong adherence characteristics, broad prescriber adoption, and continued market share gains in branded HIV treatment.

Vemlidy has produced relatively stable annual revenue. Its growth profile is slower than Biktarvy’s because HBV treatment is a more mature market and many patients remain on long-duration therapy. Descovy has a mixed outlook: treatment demand remains solid, while PrEP expansion supports volume but increases exposure to payer controls, public-health procurement, and future generic competition.

What are the main market drivers for tenofovir alafenamide?

Why is Biktarvy the leading commercial product?

Biktarvy combines bictegravir, emtricitabine, and TAF in a once-daily single-tablet regimen. Its commercial position reflects:

High efficacy across treatment-naive and treatment-experienced populations.
Once-daily dosing.
No pharmacokinetic booster.
Broad use in treatment guidelines.
Continued switching from older branded regimens.
Strong U.S. and international reimbursement.

Biktarvy’s leading competitive set includes Triumeq, Dovato, Delstrigo, Juluca, Cabenuva, and generic or branded TDF-based regimens. Long-acting Cabenuva is a differentiated alternative rather than a direct TAF substitute, while Dovato competes on a two-drug regimen and lower active-ingredient count.

How does TAF compare with TDF?

Attribute	TAF	TDF
Systemic tenofovir exposure	Lower	Higher
Renal and bone profile	Generally more favorable	Greater concern in susceptible patients
Established generic competition	Limited for newer branded combinations	Extensive
Use in HIV	Broad combination use	Broad combination use
Use in HBV	Vemlidy	Viread and generic TDF
Commercial positioning	Premium branded platform	Mature, lower-cost standard

TAF’s clinical benefit is strongest in patients for whom renal or bone exposure is a concern. TDF retains an important role because it is inexpensive, widely available, and effective in both HIV and HBV.

What is the role of Descovy in HIV PrEP?

Descovy expanded TAF beyond treatment into prevention. FDA approval for PrEP in 2019 created a second demand channel, but its commercial position is constrained by Truvada and generic emtricitabine/TDF availability.

The PrEP market has several structural features:

High public-health and government-payer exposure.
Increasing diagnosis and prevention programs.
Strong price sensitivity.
Competition from generic TDF-based PrEP.
Potential differentiation for patients with renal or bone-risk considerations.

Descovy’s PrEP opportunity is therefore clinically meaningful but less economically protected than the initial branded HIV-treatment market.

When does tenofovir alafenamide lose exclusivity?

Regulatory exclusivity has already expired for most early TAF products. Patent protection remains the more important barrier.

FDA exclusivity timeline

Product	FDA approval	Principal regulatory exclusivity position
Genvoya	2015	Early combination-product exclusivity expired
Vemlidy	2016	Five-year NCE period expired in 2021, if treated as an eligible NME
Descovy	2016	Early exclusivity expired
Odefsey	2016	Combination-product exclusivity expired
Biktarvy	2018	NCE-related exclusivity period expired or is no longer the primary barrier
Symtuza	2018	Combination-product exclusivity expired
Descovy PrEP	2019	New indication exclusivity does not replace underlying patent rights

FDA regulatory exclusivity does not establish the generic entry date. A generic applicant may file an abbreviated new drug application with a Paragraph IV certification before patent expiration, creating litigation and potentially a 30-month stay.

What patents protect tenofovir alafenamide products?

TAF protection is distributed across several patent layers:

The TAF chemical entity and prodrug.
TAF fumarate and related salt forms.
Pharmaceutical compositions.
Fixed-dose combinations.
Specific HIV regimens.
Dosing and treatment methods.
Pediatric formulations and dosage forms.
Manufacturing and crystalline-form processes.

A foundational Gilead patent family includes U.S. Patent No. 7,390,791, covering nucleotide analog technology associated with tenofovir compounds. Its practical commercial value has declined following expiration of the underlying term. Later patents covering TAF formulations, salts, combinations, and treatment methods have greater relevance to current generic-entry timing.

What formulation patents protect TAF products?

Formulation patents can cover:

TAF fumarate compositions.
Low-dose tablet formulations.
Compatibility with emtricitabine.
Combinations with bictegravir, darunavir, cobicistat, rilpivirine, or elvitegravir.
Tablet stability and dissolution characteristics.
Specific ratios of active ingredients.
Pediatric or reduced-dose formulations.

These patents can block a generic from copying a complete branded formulation even when the basic TAF molecule is no longer protected. A generic may attempt a non-infringing formulation, but bioequivalence, stability, and fixed-dose-combination requirements can increase development complexity.

What method-of-use patents protect TAF?

Method-of-use patents may cover:

Treatment of HIV infection with TAF-containing combinations.
Treatment of chronic HBV with TAF.
Switching from TDF to TAF.
PrEP use in defined patient populations.
Dosing in renal-impaired patients.
Use of a specific combination with or without a pharmacokinetic booster.

Method-of-use patents are less effective against a fully labeled generic when physicians prescribe outside the protected indication. They can remain commercially relevant where the label, product selection, or payer controls make the protected use difficult to carve out.

Which companies are challenging tenofovir alafenamide patents?

The principal generic threat comes from large generic manufacturers that can develop combination products and pursue Paragraph IV certifications. Potential challengers include Teva, Viatris, Dr. Reddy’s Laboratories, Sun Pharmaceutical, Lupin, Cipla, and multiple regional manufacturers.

Gilead’s public filings have disclosed patent litigation and patent challenges involving its HIV products. However, challenge activity is product-specific. A Paragraph IV filing against one TAF-containing product does not automatically authorize generic versions of all TAF products.

The main litigation variables are:

Whether the generic challenges the compound, formulation, or combination patent.
Whether Gilead obtains a 30-month stay.
Whether the case settles before trial.
Whether the generic receives a launch license.
Whether the settlement includes a confidential or fixed launch date.
Whether the generic product is a single agent or complete fixed-dose combination.

What is the Orange Book status of tenofovir alafenamide products?

TAF-containing prescription products are listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The listings include patents and regulatory exclusivities submitted by the reference-product sponsor.

Orange Book treatment differs by product:

Vemlidy has a standalone active ingredient and its own patent listing structure.
Descovy has patents covering the emtricitabine/TAF combination and approved uses.
Biktarvy has patents directed to the bictegravir/emtricitabine/TAF combination and related claims.
Genvoya, Odefsey, and Symtuza have combination-specific patent portfolios.

Orange Book listings do not guarantee that every listed patent will survive litigation. They identify patents that may trigger certification obligations for an ANDA applicant. FDA’s current Orange Book database is the controlling source for live listings and listed expiration dates. (FDA, 2025)

What patent litigation affects TAF products?

The most important litigation risk is delayed generic entry rather than immediate loss of the entire TAF franchise. Gilead can defend different products through separate patent families, meaning that market erosion is likely to occur sequentially.

Likely litigation sequence

Generic TDF products remain available at low prices.
Older TAF combinations face the first significant challenges.
Products with weaker commercial growth become settlement candidates.
Biktarvy remains the primary litigation and revenue priority.
Vemlidy faces a separate HBV-specific generic-entry pathway.
Generic entry initially targets individual products, not the entire TAF platform.

A settlement can permit an authorized or third-party generic launch before the latest patent expiration. The economic result depends on the launch date, royalty terms, market-share restrictions, and whether multiple generic manufacturers enter simultaneously.

How strong is the tenofovir alafenamide patent estate?

The TAF patent estate is strong at the platform level but uneven at the product level.

Strengths

Multiple branded products create layered protection.
Biktarvy combines TAF with the newer integrase inhibitor bictegravir.
Formulation and combination patents can survive compound-patent expiry.
TAF has distinct HIV and HBV indications.
Clinical switching and safety claims support commercial differentiation.
Gilead has extensive experience defending HIV patent portfolios.

Weaknesses

The underlying tenofovir platform is mature.
TDF generics constrain pricing.
Several TAF products launched between 2015 and 2018.
Fixed-dose combinations can be designed around in some cases.
Method-of-use claims may be vulnerable to skinny-label strategies.
HIV treatment guidelines can shift quickly when lower-cost alternatives emerge.

Biktarvy has the strongest commercial protection profile because its value depends on both TAF and bictegravir. Vemlidy has a more concentrated asset profile because it is a single-agent HBV product. Older products such as Genvoya and Odefsey face greater substitution risk as their therapeutic roles overlap with lower-cost alternatives.

What generic entry risks exist for TAF products?

Biktarvy

Biktarvy has the highest revenue exposure and the greatest strategic importance. Generic entry is unlikely to produce an immediate full-franchise collapse because separate patents may protect the product’s compound, combination, formulation, and use. The first launch could produce substantial price erosion even if generic penetration is limited.

Descovy

Descovy faces the highest policy and payer risk because generic TDF PrEP is widely available. A generic entrant could target treatment first, PrEP, or both, depending on patent claims and label strategy.

Vemlidy

Vemlidy’s risk is concentrated in HBV. Generic substitution may be slower than in HIV if physicians prioritize renal and bone characteristics, but price pressure can be significant in public and international markets.

Genvoya, Odefsey, and Symtuza

These products are exposed to portfolio rationalization, declining new starts, and generic competition. Their revenue may decline before complete generic entry as prescribers move patients toward Biktarvy or other preferred regimens.

Are biosimilars a risk for tenofovir alafenamide?

No. TAF is a small-molecule active ingredient, not a biologic. The relevant pathway is an ANDA for a generic drug, not a biosimilar application under the Public Health Service Act.

Biosimilar risk is therefore immaterial to TAF. The commercial risks are generic substitution, Paragraph IV litigation, authorized generics, formulary exclusion, and therapeutic switching.

What licensing deals support TAF products?

TAF commercialization has relied mainly on Gilead’s internal development and combination-product collaborations rather than a broad external licensing network.

Important collaboration structures include:

Janssen involvement in products containing darunavir or rilpivirine.
Commercial and development arrangements for combination HIV regimens.
Regional distribution and commercialization agreements.
Gilead’s internal control of the TAF platform and key combinations.

The economic impact of collaboration is product-specific. Licensing and supply arrangements can affect gross-to-net revenue, geographic rights, launch timing, and the allocation of litigation proceeds. They do not eliminate Gilead’s core exposure to TAF patent expiry.

How does the TAF market compare with competing HIV and HBV drugs?

Segment	TAF position	Main competitors	Commercial risk
HIV treatment	Strong through Biktarvy	Dovato, Triumeq, Cabenuva, generic TDF regimens	Generic entry and regimen switching
HIV PrEP	Established through Descovy	Truvada generics, Apretude	Price pressure and payer control
HBV	Stable through Vemlidy	Generic TDF, entecavir	Mature market and low-cost competition
Boosted HIV regimens	Declining or mature	Unboosted integrase regimens	Switching to Biktarvy or newer therapy
Long-acting HIV treatment	Not a direct platform	Cabenuva	Differentiated administration model

Cabenuva is the most important non-TAF innovation in HIV treatment, while lenacapavir could create additional competitive pressure if used in treatment or prevention settings. TAF products remain advantaged where oral, once-daily, single-tablet treatment is preferred.

What is the revenue exposure to tenofovir alafenamide patent expiry?

Gilead’s direct exposure is close to $20 billion in annual product revenue based on 2024 TAF-containing product sales. The exposure is concentrated:

Biktarvy accounts for roughly two-thirds of identifiable TAF revenue.
Descovy contributes more than $2.5 billion.
Vemlidy contributes about $1.1 billion.
Older TAF combinations contribute approximately $3 billion combined.

A staged generic-entry scenario would likely produce:

Early erosion in older combinations.
Moderate erosion in Descovy and Vemlidy.
The largest absolute impact from Biktarvy entry.
Continued residual revenue from non-substitutable or differentiated patient segments.
Increased pressure on Gilead’s HIV franchise gross margin.

The timing of Biktarvy generic entry is therefore more important than the loss of exclusivity for any single older TAF product.

What generic launch scenarios should investors monitor?

Scenario 1: Delayed entry

Gilead defeats or settles Paragraph IV challenges with launch dates near the last listed patent expiration. Revenue remains resilient, but price concessions increase before launch.

Scenario 2: Authorized generic or early licensed entry

Gilead permits an authorized generic or settlement-based launch. Volume may rise while net price falls. This approach can protect market share and manage the timing of broader generic entry.

Scenario 3: Single-product entry

A generic launches for Vemlidy, Descovy, or an older combination before Biktarvy. The impact is material but contained.

Scenario 4: Biktarvy-led erosion

A successful challenge against key Biktarvy patents produces rapid substitution. This is the highest-risk scenario for Gilead’s revenue base.

Where is geographic coverage strongest?

The United States is the most valuable and legally significant TAF market. Europe has substantial TAF use but generally faces earlier price controls, centralized procurement, and national reimbursement negotiations. Emerging markets have higher generic substitution and lower branded pricing.

Geographic risks include:

Earlier generic launches outside the United States.
Patent-term differences.
National reimbursement restrictions.
Compulsory licensing or public-health procurement.
Separate local patent validity outcomes.
Regional licensing and distribution arrangements.

Gilead’s U.S. HIV business drives the largest financial exposure. International volume can remain substantial after U.S. patent expiry, but revenue per patient is lower.

What manufacturing and intellectual-property barriers protect TAF?

TAF manufacturing is more complex than conventional TDF production because commercial products require:

High-purity active pharmaceutical ingredient.
Controlled salt and solid-state characteristics.
Stable low-dose tablet formulations.
Multi-ingredient blending.
Bioequivalence against branded combinations.
Specialized analytical methods.
Reliable supply of other active ingredients.

These barriers can delay generic commercialization but rarely prevent entry permanently. Manufacturing complexity is most relevant for complete fixed-dose combinations, where each active ingredient must meet regulatory and stability requirements.

Key Takeaways

TAF is a platform technology embedded in six major Gilead products.
Identifiable TAF-containing product revenue reached approximately $18.2 billion in 2023 and approximately $20 billion in 2024.
Biktarvy is the primary growth engine and the largest future patent-exposure asset.
Vemlidy provides a stable but mature HBV revenue stream.
Descovy benefits from PrEP expansion but competes with generic TDF.
Regulatory exclusivity has largely expired; patent and litigation strategy now control generic timing.
TAF faces generic, not biosimilar, competition.
Formulation, combination, and method-of-use patents are more important than the original tenofovir platform patents.
Generic erosion is likely to occur by product and jurisdiction rather than across the entire TAF portfolio at once.
The largest financial risk is successful early entry against Biktarvy.

FAQs

Does tenofovir alafenamide have a standalone generic?

Generic TAF is less commercially important than generic TAF-containing combinations. Regulatory approval depends on the reference product, formulation, indication, and applicable patents. Vemlidy is the principal single-agent TAF reference product.

Is Biktarvy protected by patents beyond TAF?

Yes. Biktarvy protection can include patents covering bictegravir, the bictegravir/emtricitabine/TAF combination, formulation characteristics, dosage, and approved uses. The product’s effective exclusivity therefore does not depend solely on TAF patents.

Will generic Descovy reduce HIV PrEP costs?

Generic entry could lower PrEP costs, but the timing depends on Paragraph IV litigation, patent settlements, FDA approval, and payer coverage. Generic TDF-based PrEP already provides a lower-cost alternative.

Which TAF product has the highest patent-value concentration?

Biktarvy has the highest economic concentration because it generates the most revenue and combines TAF with bictegravir. Vemlidy has a narrower but strategically important HBV patent profile.

Can a generic manufacturer copy a TAF combination without copying every patent claim?

A manufacturer may pursue a non-infringing formulation, a carved-out indication, or a different combination design. FDA approval does not resolve patent infringement, so the generic may still face litigation before commercial launch.

References

Gilead Sciences, Inc. (2023). 2022 annual report. https://www.gilead.com
Gilead Sciences, Inc. (2024). 2023 annual report. https://www.gilead.com
Gilead Sciences, Inc. (2025). 2024 annual report. https://www.gilead.com
U.S. Food and Drug Administration. (2015). Genvoya prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2016a). Vemlidy prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2016b). Descovy prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2018a). Biktarvy prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2018b). Symtuza prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2019). Descovy approval for pre-exposure prophylaxis. https://www.fda.gov
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov
U.S. Patent and Trademark Office. (2008). U.S. Patent No. 7,390,791. https://patents.google.com/patent/US7390791B2

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	246
Patent Applications:	1,211
DailyMed Link:	TENOFOVIR ALAFENAMIDE at DailyMed

AI Deep Research

Questions you can ask:

Summary for TENOFOVIR ALAFENAMIDE

Recent Clinical Trials for TENOFOVIR ALAFENAMIDE